(Q33208084)

23 July 2017

0 references

1 reference

title

Pharmacotherapy for social phobia (English)

1 reference

23 July 2017

0 references

D J Stein

1

1 reference

PubMed ID

15495010

23 July 2017

J C Ipser

series ordinal

2

1 reference

PubMed ID

15495010

23 July 2017

A J Balkom

series ordinal

3

1 reference

23 July 2017

18 October 2004

1 reference

Cochrane Database of Systematic Reviews

23 July 2017

1 reference

23 July 2017

4

1 reference

23 July 2017

CD001206

1 reference

Efficacy of olanzapine in social anxiety disorder: a pilot study

23 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

The assessment and treatment of performance anxiety in musicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Discontinuation of clonazepam in the treatment of social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Treatment of social phobia with clonazepam and placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Paroxetine for social anxiety and alcohol use in dual-diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Pharmacotherapy of Social Phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Effect of beta blockade and beta stimulation on stage fright

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Effect of beta blockade on singing performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

The effect of beta adrenergic blocking drugs on speakers' performance and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Effect of oxprenolol on stage-fright in musicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Oxprenolol in the treatment of examination stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Letter: Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

A Clinical Trial of Phenelzine in Anxiety Depressive and Phobic Neuroses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Stage Fright in Musicians: A Model Illustrating the Effect of Beta Blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Phenelzine efficacy in refractory social anxiety disorder: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Measuring the quality of trials: the quality of quality scales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Pharmacotherapy of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Pharmacological treatment of social anxiety disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Flooding with brevital in the treatment of agoraphobia: Countereffective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Publication bias in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Psychological and pharmacological treatments of social phobia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Drug treatment of social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Social phobia. Review of a neglected anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Full publication of results initially presented in abstracts. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Citalopram treatment of social anxiety disorder with comorbid major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Is olfactory reference syndrome an obsessive-compulsive spectrum disorder?: two cases and a discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Why sources of heterogeneity in meta-analysis should be investigated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Pharmacotherapy of social anxiety disorder at the turn of the millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Behaviour therapy and benzodiazepines: allies or antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001206.PUB2

10.1002/14651858.CD001206.PUB2

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference

PubMed ID

15495010